- Home
- TVTX vs ECAT Comparison
TVTX vs ECAT Comparison
Compare TVTX & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- ECAT
- Stock Information
- Founded
- TVTX 2008
- ECAT 2021
- Country
- TVTX United States
- ECAT United States
- Employees
- TVTX N/A
- ECAT N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- TVTX Health Care
- ECAT Finance
- Exchange
- TVTX Nasdaq
- ECAT Nasdaq
- Market Cap
- TVTX 1.5B
- ECAT 1.7B
- IPO Year
- TVTX N/A
- ECAT N/A
- Fundamental
- Price
- TVTX $18.37
- ECAT $16.66
- Analyst Decision
- TVTX Buy
- ECAT
- Analyst Count
- TVTX 12
- ECAT 0
- Target Price
- TVTX $24.58
- ECAT N/A
- AVG Volume (30 Days)
- TVTX 1.2M
- ECAT 278.6K
- Earning Date
- TVTX 02-13-2025
- ECAT 01-01-0001
- Dividend Yield
- TVTX N/A
- ECAT 9.20%
- EPS Growth
- TVTX N/A
- ECAT N/A
- EPS
- TVTX N/A
- ECAT 2.39
- Revenue
- TVTX $203,447,000.00
- ECAT N/A
- Revenue This Year
- TVTX $62.38
- ECAT N/A
- Revenue Next Year
- TVTX $57.65
- ECAT N/A
- P/E Ratio
- TVTX N/A
- ECAT $7.15
- Revenue Growth
- TVTX 57.08
- ECAT N/A
- 52 Week Low
- TVTX $5.12
- ECAT $14.02
- 52 Week High
- TVTX $20.33
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- TVTX 52.05
- ECAT 44.93
- Support Level
- TVTX $16.80
- ECAT $16.48
- Resistance Level
- TVTX $18.76
- ECAT $16.80
- Average True Range (ATR)
- TVTX 0.90
- ECAT 0.21
- MACD
- TVTX 0.02
- ECAT 0.02
- Stochastic Oscillator
- TVTX 61.57
- ECAT 51.56
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.